Vertex Pharmaceuticals Inc (VRTX: NASDAQ)
$83.23 n/a | n/a%
02/12/16 - 04:00 PM ET
Portfolios with VRTX
- Portfolio NameUser Type
- ProAdage Capital
- ContributorMonster Momentum Stocks To ...
- ContributorBreakout Stocks Of The Week...
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
Latest VRTX Headlines from TheStreet
- Jim Cramer's 'Mad Money' Recap: These Retailers Will Survive the Amazon Express 11.30.15 | 08:11 pm
- Clinton Drug Plan Cuts Market Exclusivity, Sets Mandatory R&D Spending 09.22.15 | 07:09 am
- Biotech Stocks Recover From Early-Morning Flash Crash 08.24.15 | 12:08 pm
- 50 Stocks to Watch for Good Plays: Jim Cramer's Best Blogs 08.14.15 | 09:08 pm
- 3 Stocks Boosting The Drugs Industry Higher 08.04.15 | 01:08 pm
- 3 Drugs Stocks Pushing Industry Growth 07.30.15 | 01:07 pm
- Vertex Pharmaceuticals (VRTX) Earnings Report: Q2 2015 Conference Call Transcript 07.30.15 | 10:07 am
- Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock 07.29.15 | 04:07 pm
- Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today 07.15.15 | 10:07 am
- Vertex Pharmaceuticals (VRTX) Is Today's Unusual Social Activity Stock 07.02.15 | 12:07 pm
Press Releases for VRTX
- Vertex Reports Second Quarter 2015 Financial Results - Business Wire 07.29.15 | 04:07 pm
- Vertex To Announce Second Quarter 2015 Financial Results On July 29 - Business Wire 07.14.15 | 09:07 am
- ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation - Business Wire 07.02.15 | 01:07 pm
- Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors - Business Wire 06.18.15 | 04:06 pm
- Vertex Announces Data Presentations At European Cystic Fibrosis Society (ECFS) Conference - Business Wire 06.11.15 | 09:06 am
- Vertex And Parion Sciences Establish Collaboration To Develop Epithelial Sodium Channel (ENaC) Inhibitors In Cystic Fibrosis And Other Pulmonary Diseases - Business Wire 06.04.15 | 04:06 pm
- Vertex To Present At The Goldman Sachs Healthcare Conference On June 11 - Business Wire 06.03.15 | 04:06 pm
- New England Journal Of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (lumacaftor/ivacaftor) in People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 05.17.15 | 01:05 pm
- Vertex To Present At The UBS Healthcare Conference On May 19 - Business Wire 05.13.15 | 04:05 pm
- Food And Drug Administration Advisory Panel Voted 12 To 1 To Recommend Approval Of ORKAMBI™ (lumacaftor/ivacaftor) To Treat People With Cystic Fibrosis Ages 12 And Older Who Have Two Copies Of The F508del Mutation - Business Wire 05.12.15 | 04:05 pm
Partner Headlines for VRTX
- Vertex complete response letter a minor setback, says Leerink - The Fly 02.05.16 | 10:02 am
- Vertex selloff more than accounts for Kalydeco news, says Piper Jaffray - The Fly 02.05.16 | 10:02 am
- Vertex resumed with an Outperform at Leerink - The Fly 02.05.16 | 06:02 am
- Vertex reinitiated with an Outperform at Leerink - The Fly 02.04.16 | 07:02 pm
- Vertex upgraded to Buy from Hold at Jefferies - The Fly 02.01.16 | 06:02 am
- Vertex (VRTX) Posts Narrower 4Q Loss, Maintains Outlook - Zacks 01.28.16 | 09:01 am
- Vertex price target lowered to $143 from $180 at Piper Jaffray - The Fly 01.28.16 | 05:01 am
- Checks indicate worries over Vertex Orkambi overdone, says Stifel - The Fly 01.26.16 | 07:01 am
- Vertex long-term outlook still positive, says RBC Capital - The Fly 01.22.16 | 08:01 am
- Vertex initiated with an Outperform at Credit Suisse - The Fly 01.19.16 | 05:01 pm